Pancreas Metastases From Papillary Thyroid Carcinoma: A Review of the Literature

Davidson, Maja; Olsen, Randall J.; Ewton, April A.; Robbins, Richard J.

doi:10.4158/ep-2017-0001

Cited by 27 publications

(38 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some cases were found to be associated with older patients and non-radioactive iodine avid, FDG-PET-positive metastases. 18 In one report, a patient with multiple organ sites involved by metastatic PTC showed differences in uptake of radioiodine. 4 Despite being presumably identical pathologically, the pulmonary metastases and cervical recurrence took up isotope, whereas the pancreatic metastases did not and led to the clinical consideration of another tumor type.…”

Section: Discussion/conclusionmentioning

confidence: 99%

“…The biological connections and explanations of why PTC metastasizes to the pancreas is unclear. Some cases were found to be associated with older patients and non‐radioactive iodine avid, FDG‐PET‐positive metastases . In one report, a patient with multiple organ sites involved by metastatic PTC showed differences in uptake of radioiodine .…”

Section: Discussion/conclusionmentioning

confidence: 99%

“…The reasons for the discrepancy are unclear, but differences in iodide symporter gene expression in thyroid cancers that acquire metastatic potential have been identified and are hypothesized to be an underlying mechanism within pancreatic metastases . BRAF V600E mutation is known to be associated with more aggressive forms of thyroid cancer and was detected in select cases of metastatic PTC to the pancreas . Interestingly, sorafenib, a small kinase inhibitor of the BRAF gene product has been reported to show some degree of stabilization of disease in patients with metastatic PTC .…”

Section: Discussion/conclusionmentioning

confidence: 99%

“…4,19 BRAF V600E mutation is known to be associated with more aggressive forms of thyroid cancer and was detected in select cases of metastatic PTC to the pancreas. 7,10,17,18 Interestingly, sorafenib, a small kinase inhibitor of the BRAF gene product has been reported to show some degree of stabilization of disease in patients with metastatic PTC. 7 However, further studies are needed to determine the overall efficacy and response rate to sorafenib in these patients.…”

Section: Discussion/conclusionmentioning

confidence: 99%

See 3 more Smart Citations

Papillary thyroid carcinoma metastatic to the pancreas: Case report

Cho

Acosta-Gonzalez

Brandler

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is generally associated with an excellent long‐term outcome. Distant metastasis is rare with only 5‐7% of patients developing distant disease. Metastasis of PTC to the pancreas is an exceedingly rare occurrence. To date, few cases have been reported. We present the case of an 81‐year‐old man with past medical history of PTC status post total thyroidectomy with local recurrence treated with radioactive iodine and selective neck dissection. Ten years after his initial diagnosis, PET‐CT scan revealed a new hypermetabolic 1.1 cm × 0.9 cm left lower lobe lung nodule and hypermetabolism in the proximal body of the pancreas. Follow‐up MRI cholangiogram showed a 1.0 × 0.8 cm T1 hypointense lesion in the proximal body of the pancreas. Endoscopic ultrasound‐guided fine‐needle aspiration biopsy of the pancreatic mass showed neoplastic epithelial cells arranged in papillary clusters with fibrovascular cores and syncytial sheets with high nuclear to cytoplasmic ratio, visible nucleoli, nuclear pallor, focal nuclear grooves, and rare intranuclear pseudoinclusions. Immunohistochemical stains performed on the smears showed positive nuclear expression of TTF‐1 and PAX‐8. The findings were consistent with metastatic PTC. Surgical resection of the lung nodule confirmed metastatic PTC. Pancreatic metastases usually occur after long time intervals with reports of up to 8 years in PTC. This makes the diagnosis more challenging, and metastatic disease should always be in the differential diagnosis in cases presenting with a pancreatic mass, especially in patients with a prior malignancy.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

See 2 more Smart Citations

Papillary thyroid carcinoma metastatic to the pancreas: Case report

Cho

Acosta-Gonzalez

Brandler

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…Lungs, bones, thoracic lymph nodes and nervous system are the most common organs involved (4). Unusual metastatic sites have been described in skin (5), pancreas (6), eye (7), kidney (8), adrenal (9), breast (10) and liver (11), but they do not always represent an additional negative prognostic factor for disease outcome (12).…”

Section: Introductionmentioning

confidence: 99%

Cholestatic syndrome as initial manifestation of pancreatic metastasis of papillary thyroid carcinoma: case report and review

Tramontin¹,

Faria²,

Nascimento³

et al. 2020

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Most papillary thyroid carcinomas (PTC) harbor excellent prognosis. Although rare, distant metastases normally occur in lungs and/or bones. Here we describe a rare case of pancreatic metastasis presenting with rapid onset cholestatic syndrome. A literature review was also performed. A 73-yearold man with a high risk PTC was submitted to total thyroidectomy (TT) followed by radioiodine therapy. After initial therapy, he persisted with progressive rising serum thyroglobulin levels but with no evidence of structural disease. Recently, the patient presented with a rapid onset and progressive cholestatic syndrome. A 4 cm lesion in pancreas was identified, with echoendoscopy fine-needle aspiration biopsy (FNAB) confirming a pancreatic metastasis from PTC. The patient was submitted to a successful pancreaticoduodenectomy. Pancreatic metastases of PTC are rare and few long-term follow-up data are available to guide management. Fourteen cases were former reported, mean age was 65.7 years-old with mean time between PTC and pancreatic metastasis diagnosis of 7.9 years. Nine of them had another distant metastasis, nine were diagnosed by FNAB and just two received sorafenib. Arch Endocrinol Metab. 2020;64(2):179-84

show abstract

Role of differentially expressed genes and long non‐coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis

Cai

Chen

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Currently, the combination of ultrasonography and fine-needle aspiration biopsy (FNAB) can not discriminate between benign and malignant tumor of thyroid in some cases. The main issue in assessing the patients with thyroid nodules is to distinguish thyroid cancer from benign nodules, and reduce diagnostic surgery. To identify potential molecular biomarkers for patients with indeterminate FNAB, we explored the differentially expressed genes (DEGs) and differentially expressed long non-coding RNAs (DElncRNAs) in TCGA database between 318 papillary thyroid carcinoma (PTC) tissues and 35 normal thyroid gland tissues by DESeq R. Furthermore, DEGs were verified by gene expression profile GSE33630. Ten top DEGs and DElncRNAs were identified as candidate biomarkers for diagnosis and Lasso (Least Absolute Shrinkage and Selection Operator) logistic regression analysis were performed to improve the diagnostic accuracy of them. Besides, partial molecular biomarkers of top DEGs and DElncRNAs were closely related to the tumor stage (T), lymph node metastasis (N), metastasis (M) and pathological stage of PTC, which could reflect behavior of tumor progression. According to multivariate Cox analysis, the combination of two DEGs (METTL7B and KCTD16) and two DElncRNAs (LINC02454 and LINC02471) could predict the outcome in a more exact way. In conclusion, top DEGs and DElncRNAs could raise diagnosis of PTC in indeterminate FNAB specimens, and some could function as molecule biomarkers for tumor progression and prognosis.

show abstract

Pancreas Metastases From Papillary Thyroid Carcinoma: A Review of the Literature

Cited by 27 publications

References 13 publications

Papillary thyroid carcinoma metastatic to the pancreas: Case report

Papillary thyroid carcinoma metastatic to the pancreas: Case report

Cholestatic syndrome as initial manifestation of pancreatic metastasis of papillary thyroid carcinoma: case report and review

Role of differentially expressed genes and long non‐coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis

Contact Info

Product

Resources

About